Induction and stability of the anergic phenotype in T cells

Seminars in Immunology

Volumn 25, Issue 4, 2013, Pages 313-320

  Valdor, Rut ^a   Macian, Fernando ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Anergy induction; Anergy reversal; Epigenetics; NFAT

Indexed keywords

CD28 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EARLY GROWTH RESPONSE FACTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE ZAP 70; RHEB PROTEIN; SIRTUIN 1; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR NFAT; UBIQUITIN PROTEIN LIGASE E3;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BINDING SITE; CALCIUM SIGNALING; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CLONAL ANERGY; CYTOKINE PRODUCTION; CYTOSOL; DEACETYLATION; DNA METHYLATION; ENZYME ACTIVATION; EPIGENETIC REPRESSION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PALMITOYLATION; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UBIQUITINATION; UPREGULATION;

ANERGY INDUCTION; ANERGY REVERSAL; EPIGENETICS; NFAT;

ANIMALS; CLONAL ANERGY; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; PHENOTYPE; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION, GENETIC;

EID: 84888876966     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.10.010     Document Type: Review

References (119)

1. Palmer E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol 2003, 3:383-391.
2. Hogquist K.A., Baldwin T.A., Jameson S.C. Central tolerance: learning self-control in the thymus. Nat Rev Immunol 2005, 5:772-782.
3. Wells A.D. New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J Immunol 2009, 182:7331-7341.
4. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
5. Mueller D.L. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010, 11:21-27.
6. Sytwu H.K., Liblau R.S., McDevitt H.O. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996, 5:17-30.
7. Davey G.M., Kurts C., Miller J.F., Bouillet P., Strasser A., Brooks A.G., et al. Peripheral deletion of autoreactive CD8T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J Exp Med 2002, 196:947-955.
8. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
9. Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 2008, 105:10113-10118.
10. Paust S., Lu L., McCarty N., Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 2004, 101:10398-10403.
11. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
12. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
13. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
14. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
15. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact IL-35- and IL-10-dependent manner. J Immunol 2009, 182:6121-6128.
16. Green E.A., Gorelik L., McGregor C.M., Tran E.H., Flavell R.A. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A 2003, 100:10878-10883.
17. Schwartz R.H. T cell anergy. Annu Rev Immunol 2003, 21:305-334.
18. Harding F.A., McArthur J.G., Gross J.A., Raulet D.H., Allison J.P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356:607-609.
19. Jenkins M.K., Schwartz R.H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987, 165:302-319.
20. Quill H., Schwartz R.H. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987, 138:3704-3712.
21. Macian F., Im S.H., Garcia-Cozar F.J., Rao A. T-cell anergy. Curr Opin Immunol 2004, 16:209-216.
22. Chappert P., Schwartz R.H. Induction of T cell anergy: integration of environmental cues and infectious tolerance. Curr Opin Immunol 2010, 22:552-559.
23. Bour-Jordan H., Esensten J.H., Martinez-Llordella M., Penaranda C., Stumpf M., Bluestone J.A. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 2011, 241:180-205.
24. Fraser J.D., Irving B.A., Crabtree G.R., Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991, 251:313-316.
25. Lindstein T., June C.H., Ledbetter J.A., Stella G., Thompson C.B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989, 244:339-343.
26. Boussiotis V.A., Barber D.L., Nakarai T., Freeman G.J., Gribben J.G., Bernstein G.M., et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994, 266:1039-1042.
27. Appleman L.J., van Puijenbroek A.A., Shu K.M., Nadler L.M., Boussiotis V.A. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 2002, 168:2729-2736.
28. Nourse J., Firpo E., Flanagan W.M., Coats S., Polyak K., Lee M.H., et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994, 372:570-573.
29. Rowell E.A., Walsh M.C., Wells A.D. Opposing roles for the cyclin-dependent kinase inhibitor p27kip1 in the control of CD4+ T cell proliferation and effector function. J Immunol 2005, 174:3359-3368.
30. Gao B., Kong Q., Kemp K., Zhao Y.S., Fang D. Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance. Proc Natl Acad Sci U S A 2012, 109:899-904.
31. Zhang J., Lee S.M., Shannon S., Gao B., Chen W., Chen A., et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 2009, 119:3048-3058.
32. Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
33. Lee K., Gudapati P., Dragovic S., Spencer C., Joyce S., Killeen N., et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32:743-753.
34. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
35. Delgoffe G.M., Powell J.D. mTOR: taking cues from the immune microenvironment. Immunology 2009, 127:459-465.
36. Powell J.D., Lerner C.G., Schwartz R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999, 162:2775-2784.
37. Allen A., Zheng Y., Gardner L., Safford M., Horton M.R., Powell J.D. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 2004, 172:4797-4803.
38. Colombetti S., Benigni F., Basso V., Mondino A. Clonal anergy is maintained independently of T cell proliferation. J Immunol 2002, 169:6178-6186.
39. Zheng Y., Collins S.L., Lutz M.A., Allen A.N., Kole T.P., Zarek P.E., et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007, 178:2163-2170.
40. Xie D.L., Wu J., Lou Y.L., Zhong X.P. Tumor suppressor TSC1 is critical for T-cell anergy. Proc Natl Acad Sci U S A 2012, 109:14152-14157.
41. Zheng Y., Delgoffe G.M., Meyer C.F., Chan W., Powell J.D. Anergic T cells are metabolically anergic. J Immunol 2009, 183:6095-6101.
42. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008, 224:166-182.
43. Greenwald R.J., Boussiotis V.A., Lorsbach R.B., Abbas A.K., Sharpe A.H. CTLA-4 regulates induction of anergy in vivo. Immunity 2001, 14:145-155.
44. Shrikant P., Khoruts A., Mescher M.F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999, 11:483-493.
45. Wells A.D., Walsh M.C., Bluestone J.A., Turka L.A. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001, 108:895-903.
46. Bishop K.D., Harris J.E., Mordes J.P., Greiner D.L., Rossini A.A., Czech M.P., et al. Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell Immunol 2009, 256:86-91.
47. Chikuma S., Terawaki S., Hayashi T., Nabeshima R., Yoshida T., Shibayama S., et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol 2009, 182:6682-6689.
48. Tsushima F., Yao S., Shin T., Flies A., Flies S., Xu H., et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007, 110:180-185.
49. Zarek P.E., Huang C.T., Lutz E.R., Kowalski J., Horton M.R., Linden J., et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008, 111:251-259.
50. Martinez R.J., Zhang N., Thomas S.R., Nandiwada S.L., Jenkins M.K., Binstadt B.A., et al. Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells. J Immunol 2012, 188:170-181.
51. Barber E.K., Dasgupta J.D., Schlossman S.F., Trevillyan J.M., Rudd C.E. The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc Natl Acad Sci U S A 1989, 86:3277-3281.
52. Chan A.C., Irving B.A., Fraser J.D., Weiss A. The zeta chain is associated with a tyrosine kinase and upon T-cell antigen receptor stimulation associates with ZAP-70, a 70-kDa tyrosine phosphoprotein. Proc Natl Acad Sci U S A 1991, 88:9166-9170.
53. Chan A.C., Iwashima M., Turck C.W., Weiss A. ZAP-70: a 70kD protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992, 71:649-662.
54. Isakov N., Wange R.L., Burgess W.H., Watts J.D., Aebersold R., Samelson L.E. ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity. J Exp Med 1995, 181:375-380.
55. Li Q.J., Dinner A.R., Qi S., Irvine D.J., Huppa J.B., Davis M.M., et al. CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. Nat Immunol 2004, 5:791-799.
56. Liu S.K., Fang N., Koretzky G.A., McGlade C.J. The hematopoietic-specific adaptor protein gads functions in T-cell signaling via interactions with the SLP-76 and LAT adaptors. Curr Biol 1999, 9:67-75.
57. Zhang W., Sloan-Lancaster J., Kitchen J., Trible R.P., Samelson L.E. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998, 92:83-92.
58. Sommers C.L., Rabin R.L., Grinberg A., Tsay H.C., Farber J., Love P.E. A role for the Tec family tyrosine kinase Txk in T cell activation and thymocyte selection. J Exp Med 1999, 190:1427-1438.
59. Ebinu J.O., Stang S.L., Teixeira C., Bottorff D.A., Hooton J., Blumberg P.M., et al. RasGRP links T-cell receptor signaling to Ras. Blood 2000, 95:3199-3203.
60. Krishna S., Zhong X.P. Regulation of lipid signaling by diacylglycerol kinases during T cell development and function. Front Immunol 2013, 4:178.
61. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013, 13:227-242.
62. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 2007, 7:690-702.
63. Baine I., Abe B.T., Macian F. Regulation of T-cell tolerance by calcium/NFAT signaling. Immunol Rev 2009, 231:225-240.
64. Jenkins M.K., Chen C.A., Jung G., Mueller D.L., Schwartz R.H. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990, 144:16-22.
65. Jain J., McCaffrey P.G., Miner Z., Kerppola T.K., Lambert J.N., Verdine G.L., et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993, 365:352-355.
66. Loh C., Shaw K.T., Carew J., Viola J.P., Luo C., Perrino B.A., et al. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem 1996, 271:10884-10891.
67. Okamura H., Aramburu J., Garcia-Rodriguez C., Viola J.P., Raghavan A., Tahiliani M., et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell 2000, 6:539-550.
68. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005, 5:472-484.
69. Macian F., Garcia-Rodriguez C., Rao A. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J 2000, 19:4783-4795.
70. Giffin M.J., Stroud J.C., Bates D.L., von Koenig K.D., Hardin J., Chen L. Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element. Nat Struct Biol 2003, 10:800-806.
71. Jin L., Sliz P., Chen L., Macian F., Rao A., Hogan P.G., et al. An asymmetric NFAT1 dimer on a pseudo-palindromic kappa B-like DNA site. Nat Struct Biol 2003, 10:807-811.
72. Soto-Nieves N., Puga I., Abe B.T., Bandyopadhyay S., Baine I., Rao A., et al. Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance. J Exp Med 2009, 206:867-876.
73. Macian F., Garcia-Cozar F., Im S.H., Horton H.F., Byrne M.C., Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002, 109:719-731.
74. Harris J.E., Bishop K.D., Phillips N.E., Mordes J.P., Greiner D.L., Rossini A.A., et al. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J Immunol 2004, 173:7331-7338.
75. Safford M., Collins S., Lutz M.A., Allen A., Huang C.T., Kowalski J., et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 2005, 6:472-480.
76. Zheng Y., Zha Y., Driessens G., Locke F., Gajewski T.F. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 2012, 209:2157-2163.
77. Hsiao H.W., Liu W.H., Wang C.J., Lo Y.H., Wu Y.H., Jiang S.T., et al. Deltex1 is a target of the transcription factor NFAT that promotes T cell anergy. Immunity 2009, 31:72-83.
78. Fields P.E., Gajewski T.F., Fitch F.W. Blocked Ras activation in anergic CD4+ T cells. Science 1996, 271:1276-1278.
79. Li W., Whaley C.D., Mondino A., Mueller D.L. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 1996, 271:1272-1276.
80. Anandasabapathy N., Ford G.S., Bloom D., Holness C., Paragas V., Seroogy C., et al. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 2003, 18:535-547.
81. Kriegel M.A., Rathinam C., Flavell R.A. E3 ubiquitin ligase GRAIL controls primary T cell activation and oral tolerance. Proc Natl Acad Sci U S A 2009, 106:16770-16775.
82. Nurieva R.I., Zheng S., Jin W., Chung Y., Zhang Y., Martinez G.J., et al. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 2010, 32:670-680.
83. Su L., Lineberry N., Huh Y., Soares L., Fathman C.G. A novel E3 ubiquitin ligase substrate screen identifies Rho guanine dissociation inhibitor as a substrate of gene related to anergy in lymphocytes. J Immunol 2006, 177:7559-7566.
84. Lineberry N.B., Su L.L., Lin J.T., Coffey G.P., Seroogy C.M., Fathman C.G. Cutting edge: the transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy. J Immunol 2008, 181:1622-1626.
85. Schartner J.M., Simonson W.T., Wernimont S.A., Nettenstrom L.M., Huttenlocher A., Seroogy C.M. Gene related to anergy in lymphocytes (GRAIL) expression in CD4+ T cells impairs actin cytoskeletal organization during T cell/antigen-presenting cell interactions. J Biol Chem 2009, 284:34674-34681.
86. Ichikawa D., Mizuno M., Yamamura T., Miyake S. GRAIL (gene related to anergy in lymphocytes) regulates cytoskeletal reorganization through ubiquitination and degradation of Arp2/3 subunit 5 and coronin 1A. J Biol Chem 2011, 286:43465-43474.
87. Fang D., Liu Y.C. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2001, 2:870-875.
88. Gao M., Labuda T., Xia Y., Gallagher E., Fang D., Liu Y.C., et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 2004, 306:271-275.
89. Heissmeyer V., Macian F., Im S.H., Varma R., Feske S., Venuprasad K., et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 2004, 5:255-265.
90. Jeon M.S., Atfield A., Venuprasad K., Krawczyk C., Sarao R., Elly C., et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004, 21:167-177.
91. Huang H., Jeon M.S., Liao L., Yang C., Elly C., Yates J.R., et al. K33-linked polyubiquitination of T cell receptor-zeta regulates proteolysis-independent T cell signaling. Immunity 2010, 33:60-70.
92. Puga I., Rao A., Macian F. Targeted cleavage of signaling proteins by caspase 3 inhibits T cell receptor signaling in anergic T cells. Immunity 2008, 29:193-204.
93. Olenchock B.A., Guo R., Carpenter J.H., Jordan M., Topham M.K., Koretzky G.A., et al. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol 2006, 7:1174-1181.
94. Zha Y., Marks R., Ho A.W., Peterson A.C., Janardhan S., Brown I., et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 2006, 7:1166-1173.
95. Hundt M., Tabata H., Jeon M.S., Hayashi K., Tanaka Y., Krishna R., et al. Impaired activation and localization of LAT in anergic T cells as a consequence of a selective palmitoylation defect. Immunity 2006, 24:513-522.
96. Tzachanis D., Freeman G.J., Hirano N., van Puijenbroek A.A., Delfs M.W., Berezovskaya A., et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001, 2:1174-1182.
97. Powell J.D., Lerner C.G., Ewoldt G.R., Schwartz R.H. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol 1999, 163:6631-6639.
98. Bandyopadhyay S., Dure M., Paroder M., Soto-Nieves N., Puga I., Macian F. Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood 2007, 109:2878-2886.
99. Thomas R.M., Chunder N., Chen C., Umetsu S.E., Winandy S., Wells A.D. Ikaros enforces the costimulatory requirement for IL2 gene expression and is required for anergy induction in CD4+ T lymphocytes. J Immunol 2007, 179:7305-7315.
100. Baine I., Basu S., Ames R., Sellers R.S., Macian F. Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J Immunol 2013, 190:1008-1016.
101. Pan F., Yu H., Dang E.V., Barbi J., Pan X., Grosso J.F., et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 2009, 325:1142-1146.
102. Bandyopadhyay S., Montagna C., Macian F. Silencing of the Il2 gene transcription is regulated by epigenetic changes in anergic T cells. Eur J Immunol 2012, 42:2471-2483.
103. Bruniquel D., Schwartz R.H. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 2003, 4:235-240.
104. Thomas R.M., Saouaf S.J., Wells A.D. Superantigen-induced CD4+ T cell tolerance is associated with DNA methylation and histone hypo-acetylation at cytokine gene loci. Genes Immun 2007, 8:613-618.
105. Villarino A.V., Katzman S.D., Gallo E., Miller O., Jiang S., McManus M.T., et al. Posttranscriptional silencing of effector cytokine mRNA underlies the anergic phenotype of self-reactive T cells. Immunity 2011, 34:50-60.
106. Ramsdell F., Fowlkes B.J. Maintenance of in vivo tolerance by persistence of antigen. Science 1992, 257:1130-1134.
107. Beverly B., Kang S.M., Lenardo M.J., Schwartz R.H. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992, 4:661-671.
108. Dure M., Macian F. IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol Immunol 2009, 46:999-1006.
109. Brown I.E., Blank C., Kline J., Kacha A.K., Gajewski T.F. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 2006, 177:4521-4529.
110. Kline J., Brown I.E., Zha Y.Y., Blank C., Strickler J., Wouters H., et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008, 14:3156-3167.
111. Kline J., Zhang L., Battaglia L., Cohen K.S., Gajewski T.F. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol 2012, 188:2630-2642.
112. Schietinger A., Delrow J.J., Basom R.S., Blattman J.N., Greenberg P.D. Rescued tolerant CD8T cells are preprogrammed to reestablish the tolerant state. Science 2012, 335:723-727.
113. Vendetti S., Chai J.G., Dyson J., Simpson E., Lombardi G., Lechler R. Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol 2000, 165:1175-1181.
114. Haxhinasto S., Mathis D., Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008, 205:565-574.
115. Weiner H.L., da Cunha A.P., Quintana F., Wu H. Oral tolerance. Immunol Rev 2011, 241:241-259.
116. MacKenzie D.A., Schartner J., Lin J., Timmel A., Jennens-Clough M., Fathman C.G., et al. GRAIL is up-regulated in CD4(+) CD25(+) T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 2007, 282:9696-9702.
117. Okamura T., Fujio K., Shibuya M., Sumitomo S., Shoda H., Sakaguchi S., et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci U S A 2009, 106:13974-13979.
118. Tone Y., Furuuchi K., Kojima Y., Tykocinski M.L., Greene M.I., Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008, 9:194-202.
119. Wu Y.Q., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.